Myeloma Bone Disease
- 1 November 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 24 (11) , 1783-1788
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaBlood, 2009
- Bortezomib induces osteoblast differentiation via Wnt-independent activation of β-catenin/TCF signalingBlood, 2009
- Heparanase Stimulation of Protease Expression Implicates It as a Master Regulator of the Aggressive Tumor Phenotype in MyelomaJournal of Biological Chemistry, 2008
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivoAmerican Journal of Hematology, 2008
- Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growthBlood, 2008
- Cathepsin G Enhances Mammary Tumor–Induced Osteolysis by Generating Soluble Receptor Activator of Nuclear Factor-κB LigandCancer Research, 2008
- Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myelomaBlood, 2008
- The pathogenesis of the bone disease of multiple myelomaBone, 2008
- Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivoBlood, 2008
- Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivoBlood, 2006